Chemspace Drug Repurposing Description Drug discovery is a - PowerPoint PPT Presentation

Dec 16, 2022 •529 likes •603 views

Chemspace Drug Repurposing Description Drug discovery is a cost-consuming process. Different strategies exist to reduce the costs and maximize the outcome. Drug repurposing is one of the approaches, also referred to as drug repositioning or

Chemspace Drug Repurposing
Description Drug discovery is a cost-consuming process. Different strategies exist to reduce the costs and maximize the outcome. Drug repurposing is one of the approaches, also referred to as drug repositioning or reprofiling. This approach includes investigations on the unknown activity of the marketed or discontinued drugs or candidates to have the unforeseen activity.
Selection Chemspace offers the set of in-stock compounds that have a proven activity. The data on a target, mechanism of action, and a clinical status are taken various sources and included into the SD-file. Target, mechanism of action, clinical status are included • Ordering options: full set or cherry-picked selection • Library size : 866 in-stock compounds You can order full set or selected subset based on your criteria; all compounds are supplied as powders, solutions, or dry films. Please contact us at sales@chem-space.com for more information.
Chemspace Compound sets Discover our Fragment Libraries : General Fragments Fluorine and Heavy Fragments • • 3D-Shaped Fragments Selected Fragments • • Acid and Amine Fragments Singleton Fragments • • Covalent Fragments Saturated and Spiro Fragments • • All libraries’ names are clickable links. Visit www.chem-space.com/flyers to find more Chemspace presentations!
Chemspace Compound sets Discover our Screening compounds : ChEMBL analogs High QED compounds • • CNS-Focused library Phenotypic Screening set • • Covalent Modifiers PPI Modulators • • Drug Impurities Pre-Plated compounds • • Drug Repurposing RNA-Targeted library • • Framework-Derived set Virtual Screening set • • All libraries’ names are clickable links. Visit www.chem-space.com/flyers to find more Chemspace presentations!
Thank You! The Chemspace Team

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Chemspace Drug Impurities Description Drug impurities are undesirable compounds that accompany

Chemspace Drug Impurities Description Drug impurities are undesirable compounds that accompany the main drug. They are the result of side processes that are inevitable in large-scale organic synthesis. It is very important to collect data on

818 views • 6 slides

Chemspace Phenotypic Screening Set Description Phenotypic screening (PS) is one of the two major

Chemspace Phenotypic Screening Set Description Phenotypic screening (PS) is one of the two major approaches at early stage drug discovery projects, apart from the target-based screens. PS is focused on the overall effect a drug molecule causes

337 views • 6 slides

Chemspace ChEMBL sets Description Searching analogs to compounds with the known activity is

Chemspace ChEMBL sets Description Searching analogs to compounds with the known activity is helpful in hit expansion and repurposing projects. ChEMBL database has become an important reference tool containing an information on potency,

338 views • 6 slides

Chemspace Covalent Modifiers Description Compounds that possess moieties able to react with

Chemspace Covalent Modifiers Description Compounds that possess moieties able to react with biological molecules in the cell have been overlooked in drug discovery research projects for a long time. Character of the investigation did not allow

120 views • 7 slides

Chemspace Saturated Fragments Description With shift from the highly aromatic/olefinic compounds

Chemspace Saturated Fragments Description With shift from the highly aromatic/olefinic compounds to the fsp3-enriched ones, toxic properties of the drug candidates have had tendency to lower, and ADMET profiles, in general, have changed

113 views • 7 slides

for Drug Repurposing with Probabilistic Similarity Logic SHOBEIR FAKHRAEI* LOUIQA RASCHID LISE

Drug-Target Interaction Prediction for Drug Repurposing with Probabilistic Similarity Logic SHOBEIR FAKHRAEI* LOUIQA RASCHID LISE GETOOR University of Maryland, College Park, MD, USA Outline Drug Repurposing Drug-Target Interaction

851 views • 57 slides

Chemspace General Fragments Description Fragment-based approach has emerged as a powerful tool

Chemspace General Fragments Description Fragment-based approach has emerged as a powerful tool in modern drug discovery. Most of the hits from conventional screening would hardly fit the Lipinski rules, not to say the Ro4. Thus, stricter rules

326 views • 7 slides

Chemspace Heavy Fragments Description Aside of NMR, X ray crystallography is a technique that

Chemspace Heavy Fragments Description Aside of NMR, X ray crystallography is a technique that is often used to determine/prove the interaction of the molecule with target protein. Fragments for this type of screening are brominated small

455 views • 6 slides

Chemspace Framework-Derived Set Description We are willing to provide our users with various

Chemspace Framework-Derived Set Description We are willing to provide our users with various tools and services to simplify selection of the compounds from our database. Among the tools, we have fast online chemical search, custom

261 views • 6 slides

Chemspace KNIME nodes Chemspace Search Chemspace KNIME nodes Chemspace Search and Chemspace

Chemspace KNIME nodes Chemspace Search Chemspace KNIME nodes Chemspace Search and Chemspace Expanded Search nodes Source: - Chemspace database , 130 million molecules - REAL Database , 720 million molecules Search options: -

653 views • 8 slides

Chemspace Selected Fragments Description Hit follow-up usually shifts its physChem parameters to

Chemspace Selected Fragments Description Hit follow-up usually shifts its physChem parameters to less desirable area. Initial library of high quality is a key to enhance the probability of hit obtaining and chance that is would be suitable for

837 views • 6 slides

Chemspace Covalent Fragments Description Many drugs people have been using for a really long

Chemspace Covalent Fragments Description Many drugs people have been using for a really long time are actually covalent binders. Examples of covalent modifiers include cancer and arthritis treatments and as antibacterial and antiviral agents.

207 views • 7 slides

High Efficiency Drug Repurposing for New Antifungal Agents Jong H. Kim 1, *, Kathleen L. Chan 1 ,

High Efficiency Drug Repurposing for New Antifungal Agents Jong H. Kim 1, *, Kathleen L. Chan 1 , Luisa W. Cheng 1 , Lisa A. Tell 2 , Barbara A. Byrne 3 , Kristin Clothier 3,4 , and Kirkwood M. Land 5 1 Foodborne Toxin Detection and Prevention

448 views • 25 slides

Chemspace Virtual Screening Set Description Virtual screening (VS) has been a tool to identify

Chemspace Virtual Screening Set Description Virtual screening (VS) has been a tool to identify primary hits, to study structure-activity relationship, and to tweak the structures using scaffold hopping, to name a few. VS enables screening

259 views • 7 slides

Chemspace RNA-targeted library Description RNAs participate in more cell mechanisms than it has

Chemspace RNA-targeted library Description RNAs participate in more cell mechanisms than it has been thought before. Aside from transferring information from the DNA, this type of biomolecules appears to affect numerous cell processes: very

426 views • 6 slides

Drug repurposing and therapeutic anti-miRNA predictions in oxLDL-induced the proliferation of

Drug repurposing and therapeutic anti-miRNA predictions in oxLDL-induced the proliferation of vascular smooth muscle cell associated diseases Shun-Tsung Chen, Chien-Hung Huang, Victor C. Kok, Chi-Ying F Huang, Jin-Shuei Ciou, Jeffrey J. P. Tsai,

689 views • 51 slides

Digitally Augmented Homes: Telehealth for Smart Homes George Demiris PhD, FACMI March 26, 2014

Digitally Augmented Homes: Telehealth for Smart Homes George Demiris PhD, FACMI March 26, 2014 Introduction/ Definitions Examples A Case Study Discussion Smart homes Origins of the concept in the late 1970s and the 1980s:

745 views • 38 slides

founded in Galveston, Texas March 19, 1905 by William L. Moody, Jr His grandson, Robert L.

American National was founded in Galveston, Texas March 19, 1905 by William L. Moody, Jr His grandson, Robert L. Moody Jr is our current Chairman Bonnie and Clyde had life insurance issued by the American National Insurance Company of

407 views • 36 slides

Long Term Care Council Direct Care Work Force Presentation Pattie Wright - Administrator

Long Term Care Council Direct Care Work Force Presentation Pattie Wright - Administrator pwright@amerihealthcaritas.com Susan McAllister, MD Chief Medical Officer smcallister@amerihealthcaritas.com August 23, 2018 Outreach & Access

239 views • 5 slides

(F309 End of Life) Interpretive Guidance Investigative Protocol 2 483.25 End of Life Each

483.25 Quality of Life (F309 End of Life) Interpretive Guidance Investigative Protocol 2 483.25 End of Life Each resident must receive and the facility must provide the necessary care and services to attain or maintain the highest

441 views • 31 slides

Student Drug Testing for Activities Students Holly Nevels, Assistant Superintendent Justin

Student Drug Testing for Activities Students Holly Nevels, Assistant Superintendent Justin Milner, Chief Operating Officer June 3, 2019 UPDATE July 2018 Policy Approval, Implementation Consent and Opt-In Forms Counseling and

600 views • 20 slides

CDER New Drug Review: 2016 Update John K. Jenkins, M.D. Director Office of New Drugs Center

CDER New Drug Review: 2016 Update John K. Jenkins, M.D. Director Office of New Drugs Center for Drug Evaluation and Research FDA/CMS Summit December 14, 2016 Housekeeping Data and analyses presented on the following slides are thought

652 views • 37 slides

Translational Considerations in Drug Development Sarah Hollingsworth Holly Lisanby, MD

Translational Considerations in Drug Development Sarah Hollingsworth Holly Lisanby, MD Director, Translational Research Division, National Institute of Mental Health Director, Noninvasive Neuromodulation Unit, Experimental Therapeutics and

219 views • 11 slides

Project CLEAN : Research Partner Presentation September 4, 2018 Working Paper #CLEAN-2018-15

DRAFT NOT for distribution outside of the Project CLEAN Steering Committee Project CLEAN : Research Partner Presentation September 4, 2018 Working Paper #CLEAN-2018-15 Janelle Duda-Banwar, jmdgcj@rit.edu Kayla Macano, kmmgcj@rit.edu John

453 views • 7 slides